Literature DB >> 23796709

Piperlongumine selectively kills glioblastoma multiforme cells via reactive oxygen species accumulation dependent JNK and p38 activation.

Ju Mei Liu1, Feng Pan, Li Li, Qian Rong Liu, Yong Chen, Xin Xin Xiong, Kejun Cheng, Shang Bin Yu, Zhi Shi, Albert Cheung-Hoi Yu, Xiao Qian Chen.   

Abstract

Piperlongumine (PL), a natural alkaloid isolated from the long pepper, may have anti-cancer properties. It selectively targets and kills cancer cells but leaves normal cells intact. Here, we reported that PL selectively killed glioblastoma multiforme (GBM) cells via accumulating reactive oxygen species (ROS) to activate JNK and p38. PL at 20μM could induce severe cell death in three GBM cell lines (LN229, U87 and 8MG) but not astrocytes in cultures. PL elevated ROS prominently and reduced glutathione levels in LN229 and U87 cells. Antioxidant N-acetyl-L-cysteine (NAC) completely reversed PL-induced ROS accumulation and prevented cell death in LN229 and U87 cells. In LN229 and U87 cells, PL-treatment activated JNK and p38 but not Erk and Akt, in a dosage-dependent manner. These activations could be blocked by NAC pre-treatment. JNK and p38 specific inhibitors, SB203580 and SP600125 respectively, significantly blocked the cytotoxic effects of PL in LN229 and U87 cells. Our data first suggests that PL may have therapeutic potential for one of the most malignant and refractory tumors GBM.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  2′-,7′-dichlorofluorescin diacetate; 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Apoptosis; Brain tumor; Cancer therapy; DCFH-DA; DMEM; DMSO; Dulbecco’s modified Eagle’s medium; FBS; FCM; GBM; GSH; Glioma; JNK; MTT; N-acetyl-l-cysteine; NAC; Oxidative stress; PBS; PI; PL; Piplartine; ROS; c-jun N-terminal kinase; dimethyl sulfoxide; fetal bovine serum; flow cytometry; glioblastoma multiforme; glutathione; phosphate buffered saline; piperlongumine; propidium iodide; reactive oxygen species

Mesh:

Substances:

Year:  2013        PMID: 23796709     DOI: 10.1016/j.bbrc.2013.06.042

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  28 in total

Review 1.  JNK signaling as a target for anticancer therapy.

Authors:  Kamal S Abdelrahman; Heba A Hassan; Salah A Abdel-Aziz; Adel A Marzouk; Atsushi Narumi; Hiroyuki Konno; Mohamed Abdel-Aziz
Journal:  Pharmacol Rep       Date:  2021-03-12       Impact factor: 3.024

2.  Zinc Potentiates Lipopolysaccharide-induced Nitric Oxide Production in Cultured Primary Rat Astrocytes.

Authors:  Mitsuaki Moriyama; Shunsuke Fujitsuka; Kenji Kawabe; Katsura Takano; Yoichi Nakamura
Journal:  Neurochem Res       Date:  2017-11-09       Impact factor: 3.996

3.  Structural and Biochemical Analyses Reveal the Mechanism of Glutathione S-Transferase Pi 1 Inhibition by the Anti-cancer Compound Piperlongumine.

Authors:  Wayne Harshbarger; Sudershan Gondi; Scott B Ficarro; John Hunter; Durga Udayakumar; Deepak Gurbani; William D Singer; Yan Liu; Lianbo Li; Jarrod A Marto; Kenneth D Westover
Journal:  J Biol Chem       Date:  2016-11-21       Impact factor: 5.157

4.  JNK signaling pathway is involved in piperlongumine-mediated apoptosis in human colorectal cancer HCT116 cells.

Authors:  Wen Li; Chuangyu Wen; Haiyan Bai; Xiaoyan Wang; Xiaoli Zhang; Lanlan Huang; Xiangling Yang; Aikichi Iwamoto; Huanliang Liu
Journal:  Oncol Lett       Date:  2015-06-11       Impact factor: 2.967

Review 5.  Oxidative stress in bladder cancer: an ally or an enemy?

Authors:  Fernando Mendes; Eurico Pereira; Diana Martins; Edgar Tavares-Silva; Ana Salomé Pires; Ana Margarida Abrantes; Arnaldo Figueiredo; Maria Filomena Botelho
Journal:  Mol Biol Rep       Date:  2021-03-17       Impact factor: 2.316

6.  Piperlongumine induces apoptotic and autophagic death of the primary myeloid leukemia cells from patients via activation of ROS-p38/JNK pathways.

Authors:  Xin-xin Xiong; Ju-mei Liu; Xin-yao Qiu; Feng Pan; Shang-bin Yu; Xiao-qian Chen
Journal:  Acta Pharmacol Sin       Date:  2015-01-26       Impact factor: 6.150

7.  Piperlongumine treatment inactivates peroxiredoxin 4, exacerbates endoplasmic reticulum stress, and preferentially kills high-grade glioma cells.

Authors:  Tae Hyong Kim; Jieun Song; Sung-Hak Kim; Arav Krishnavadan Parikh; Xiaokui Mo; Kamalakannan Palanichamy; Balveen Kaur; Jianhua Yu; Sung Ok Yoon; Ichiro Nakano; Chang-Hyuk Kwon
Journal:  Neuro Oncol       Date:  2014-05-30       Impact factor: 12.300

8.  Allosteric Antagonist Modulation of TRPV2 by Piperlongumine Impairs Glioblastoma Progression.

Authors:  João Conde; Ruth A Pumroy; Charlotte Baker; Tiago Rodrigues; Ana Guerreiro; Bárbara B Sousa; Marta C Marques; Bernardo P de Almeida; Sohyon Lee; Elvira P Leites; Daniel Picard; Amrita Samanta; Sandra H Vaz; Florian Sieglitz; Maike Langini; Marc Remke; Rafael Roque; Tobias Weiss; Michael Weller; Yuhang Liu; Seungil Han; Francisco Corzana; Vanessa A Morais; Cláudia C Faria; Tânia Carvalho; Panagis Filippakopoulos; Berend Snijder; Nuno L Barbosa-Morais; Vera Y Moiseenkova-Bell; Gonçalo J L Bernardes
Journal:  ACS Cent Sci       Date:  2021-04-14       Impact factor: 14.553

9.  Heme oxygenase-1 determines the differential response of breast cancer and normal cells to piperlongumine.

Authors:  Ha-Na Lee; Hyeon-Ok Jin; Jin-Ah Park; Jin-Hee Kim; Ji-Young Kim; BoRa Kim; Wonki Kim; Sung-Eun Hong; Yun-Han Lee; Yoon Hwan Chang; Seok-Il Hong; Young Jun Hong; In-Chul Park; Young-Joon Surh; Jin Kyung Lee
Journal:  Mol Cells       Date:  2015-03-20       Impact factor: 5.034

10.  Na/K-ATPase as a target for anticancer drugs: studies with perillyl alcohol.

Authors:  Diogo Gomes Garcia; Hugo Caire de Castro-Faria-Neto; Camila Ignácio da Silva; Kauê Francisco Correa de Souza e Souza; Cassiano Felippe Gonçalves-de-Albuquerque; Adriana Ribeiro Silva; Lidia Maria da Fonte de Amorim; Aline Soares Freire; Ricardo Erthal Santelli; Luan Pereira Diniz; Flávia Carvalho Alcantara Gomes; Mauro Velho de Castro Faria; Patrícia Burth
Journal:  Mol Cancer       Date:  2015-05-15       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.